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Abstract: Pain is the most common and disabling non-motor symptom in patients with cervical
dystonia. Here, we report four patients with painful cervical dystonia in whom burst spinal cord
stimulation (SCS) in the cervical region produced sustained and significant improvements in both
dystonic pain and motor symptoms. Further studies need to be performed to investigate the clinical
efficacy of burst SCS for patients with cervical dystonia.
Keywords: cervical dystonia; burst spinal cord stimulation; neuropathic pain; movement disorder
1. Introduction
Cervical dystonia (CD), the most common form of focal dystonia, is characterized by involuntary
contractions of neck muscles that frequently cause repetitive twisting movement or abnormal
posture [1,2]. Patients with CD often experience intractable pain in the cervical region [1–3]. Pain in
patients with CD is considered to originate from muscles and reflects altered central processing of
nociceptive stimuli caused by sustained muscle contraction and dysfunction of the neurotransmission
system involving the basal ganglia nuclei [4,5]. Spinal cord stimulation (SCS) using the tonic stimulation
mode has been used as an effective treatment for intractable neuropathic pain caused by a wide variety
of etiologies [6]. Intriguingly, SCS has also been utilized for the treatment of movement disorders that
include focal dystonia [7,8]. Based on the observation that sensory stimulation, i.e., a sensory trick,
can dampen the severity of dystonic symptoms, tonic SCS of the cervical region, i.e., the C1–C2 level,
was previously used for the treatment of CD [7,9]; however, its long-term effects on dystonic motor
symptoms remain to be determined [8]. Burst SCS has recently emerged as an alternative intervention
for pain reduction without the mandatory paresthesia [10]. A growing body of evidence indicates that
in neuropathic patients, burst SCS can relieve pain while simultaneously improving functional and
psychological outcomes [11]. In this single-center case series, we present the therapeutic impact of
burst SCS in patients with painful CD.
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2. Materials and Methods
2.1. Patients
Patients with burst SCS fulfilling the following criteria were included in the study: (1) diagnosis
of CD refractory to ordinary medical treatments, (2) male or female aged 18–80 years, (3) intractable
pain not caused by an etiology other than CD, and (4) written informed consent to participate in
the study. The clinical characteristics of four patients with painful CD who underwent burst SCS
are summarized in Table 1. Preoperative magnetic resonance imaging showed no apparent brain or
spinal cord lesions in any of the patients. At the time of surgery, the mean age was 62 (range 51–75)
years and the mean disease duration was 11 (range 5–20) years. Three patients, except for Patient 4,
had previously received botulinum toxin (BTX) therapy, without satisfactory outcomes. No patient had
received BTX for at least 3 years prior to surgery. All patients received medical treatment that included
clonazepam (1.0–3.0 mg/day), trihexyphenidyl (3.0–12 mg), valproic acid (600 mg/day), tizanidine
(3 mg/day), or baclofen (15 mg/day) before and after the surgery. After receiving a detailed explanation
of the surgery, all patients provided written informed consent.
Table 1. Clinical summary of patients with painful cervical dystonia who underwent burst spinal
cord stimulation.
Patient
1 2 3 4
Age (year)/sex 51/F 51/F 71/F 75/M
Duration of disease (year) 8 5 20 5
Follow-up after surgery
(months) 42 24 6 12
VAS scores
Preop 85 88 77 85
Last follow-up 0 0 0 15
Percent improvement (%) 100 100 100 82.4
SF-MPQ2 scores
Preop 105 48 52 88
Last follow-up 0 0 0 10
Percent improvement (%) 100 100 100 88.6
WSTRS scores
Preop 49 48.5 53 36.5
Last follow-up 23 24 34 14.5
Percent improvement (%) 53.1 50.5 35.8 60.3
BFMDRS motor scores
Preop 9 6 29 21
Last follow-up 1.5 0.5 6 5.5
Percent improvement (%) 83.3 91.7 79.3 73.8
Abbreviations: F, female; M, male; VAS, visual analog scale; SF-MPQ2, Short-Form McGill Pain Questionnaire;
TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale; BFMDRS, Burke–Fahn–Marsden Dystonia Rating Scale.
2.2. Clinical Assessments
For subjective measurements of pain severity, the visual analog scale (VAS) and the Japanese
version of the Short-Form McGill Pain Questionnaire, which provides a list of Japanese words that
describe some of the different qualities of pain [12], were used. For evaluating the severity of
dystonic motor symptoms, we also carried out video image analysis to measure the Toronto Western
Spasmodic Torticollis Rating Scale (TWSTRS) scores and the Burke–Fahn–Marsden Dystonia Rating
Scale (BFMDRS) scores.
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2.3. Surgical Procedures
The surgery was performed under local anesthesia. For the trial, two Octrode® leads (Abbott Medical,
Plano, TX, USA) were inserted percutaneously into the epidural space of the spine under X-ray radioscopy.
The upper edges of both electrodes were finally positioned slightly lateral to the midline at the C2 level after
obtaining the stimulation-induced paresthesia over the region of dystonic pain (Figure 1). During the trial
period, a pulse generator was connected to the electrodes outside the body to conduct burst stimulation SCS.
The stimulation parameters comprised the delivery of five spikes at 500 Hz, 40 times per second, with a
pulse width of 1000 µS. The stimulation intensity was set to 50% of the sensory threshold. The combination
of stimulation electrodes was changed daily to determine optimal stimulating paradigms to achieve the
best pain relief. On the last day of the 7-day trial period, the percutaneous trial leads were removed. A few
weeks after the trial period, the patients underwent permanent implantation of a pulse generator and two
Octrode® leads (Abbott Medical, Plano, TX, USA) through the same procedure used in the trial stimulation
under local anesthesia. The parameters for stimulation were set to those used to achieve optimal stimulation
in the trial periods. Burst SCS was continuously performed during the follow-up periods. The position
of the leads was confirmed by X-ray on the day after the operation and at least once a year during the
follow-up period.
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Figure 1. Postoperative cervical X-ray images following spinal cord stimulation. (A) Anteroposterior
and (B) lateral view.
2.4. Statistical Analysis
With respect to he four clini al assessm nts (TWSTRS and BFDRS), the tudent’s -test following
Shapiro–Wilk no mality test was employed to assess the st tistical significance between preoperative
bas lin nd the last follow-up. All values were expres ed as mean ± S.D. p-Values of less than 0.05
w re considered to be statistically significant.
3. Results
All four patients with painful CD underwent burst SCS in the cervical region. There were no
issues related to lead movement during the follow-up period. No perioperative complication was
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reported in any patients. The mean follow-up period was 21 months (range: 6–42 months). The clinical
outcomes of the four patients with painful CD who underwent burst SCS are summarized in Figure 2.
According to the Shapiro–Wilk test for normality, TWSTRS and BFDRS were normally distributed
(p > 0.05 for both).
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Figure 2. Clinical outcomes of patients with painful cervical dystonia who underwent cervical burst spinal
cord stimulation. (A) Visual analog scale (VAS), (B) Short-Form McGill Pain Questionnaire (SF-MPQ-2),
(C) Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), and (D) Burke–Fahn–Marsden Dystonia
Rating Scale (BFMDRS).
3.1. Relief of Dystonic Pain
Burst SCS led to a marked improvement in dystonic pain in all patients who did not report pain
relapse after th pain relief by SCS. As shown in Figure 2A, the mean VAS score decreased from
83.8 ± 2.4 (range, 77–88) at aseline to 3.8 ± 3.8 (ran e, 0–15) at last follow-up. The mean improvement
in VAS was 95.6% ± 8.8% (range, 2.4%–100%). As shown in Figure 2B, the mean SF-MPQ2 score
also decreased from 73.3 ± 13.9 (range, 48–105) at baseline to 2.5 ± 2.5 (rang , 0–10) at last follow-up.
The mean improvement in SF-MPQ2 was 97.2% ± 5.7% (range, 88.6%–10 %).
3.2. Relief of Dystonic Motor Symptoms
Burst SCS led to a significant improvement in dystonic motor symptoms in all patients; the dystonic
postures and movements were progressi ly alleviated by the burst SCS. As hown in Figure 2C,
the mean TWSTRS score decreased from 46.8 ± 3.6 (range, 36.5–53.0) a baseline to 23.9 ± 4.0 (range,
14.5–34.0) at last follow-up (p < 0.001). The mean i provement in TWSTRS was 49.9% ± 10.3% (range,
35.8%–60.3%). As shown in Figure 2D, the mean BFMDRS score also decreased from 16.3 ± 5.3 (range,
6–29) at bas line to 3.4 ± 1.3 (range, 0.5–6.0) at last follow-up (p < 0.05). The mean imp ovement in
BFMDRS w s 82.1% ± 7.6% (range, 73.8%–91.9%).
4. Discussion
Patients with CD often suffer from intractable dystonic pain [1–3]. The present study revealed that
burst SCS achieved long-lasting, significant relief in CD-associated pain in four patients with painful
CD, similar to that observed in patients with other neuropathic pain [10,11]. Although the mechanism
underlying dystonia-associated pain remains unclear, it has been proposed that it is associated with
not only nociceptive stimuli of muscular origin but also alterations in the central nervous system
processing [4,5]. Through large, myelinated Aβ afferents whose collaterals ascend in the dorsal
column, SCS can act on the reticular system that modulates the activities of deep brain nuclei [13–15].
In particular, by mimicking the brain activity, burst SCS can induce dynamic remote effects on cortical
cells through “burst” firing of thalamic relay cells [16–18]. This evidence suggests that burst SCS exerts
a therapeutic effect on dystonia-associated pain via both peripheral and central mechanisms.
This open-label study is the first to show that burst SCS can produce sustained and significant
improve ent in the motor symptoms of patients with CD during a long mean follow-up period of
21 months (range, 6–42 months). Since the first study by Gildenberg, who reported good results
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with tonic SCS utilizing high frequencies (800–1100 Hz) at the C1–C2 level for the treatment of
CD [9], several studies reported the therapeutic efficacy of this approach on CD and other types of
dystonia [19–22]. Dieckmann et al. also reported that continuous 1100–Hz stimulation at the C2–C4
level resulted in good outcomes at 8–12 months follow-up in patients with CD [19]. Waltz et al. reported
a large series of 129 dystonic patients treated with cervical SCS. In 66 CD patients, 77% demonstrated
some improvement, including 38% with marked improvement in dystonic symptoms [7]. Conversely,
Fahn reported negative results, with only one patient experiencing long-lasting benefit among
25 patients with dystonia, and questioned the clinical efficacy of cervical SCS [20]. Furthermore,
Broseta et al. reported poor outcomes after a mean follow-up of 41.4 months in patients treated with
SCS utilizing 200–1400 Hz at the level of C2 [21]. Following these controversial results, Goetz et al.
conducted a double-blind crossover trial of cervical SCS for dystonic patients and reported that dystonic
symptoms were not significantly improved [22]. Based on the currently available data, it is likely
that tonic SCS might provide significant short-term, but not long-term, relief of motor symptoms in
patients with CD [8]. The placebo effect of mechanical sensation has been suggested as a reason for the
negative outcomes following tonic SCS [8,23,24]. Therefore, we propose that burst SCS is useful to
distinguish a responding patient without the placebo effect because burst SCS is known not to cause
stimulation-induced paresthesia [10].
SCS is generally accepted to have the ability to alleviate the motor symptoms of CD by interrupting
the tonic neck reflex pattern that is regulated by propriospinal fibers [9]. Conversely, SCS might
also exert an ascending remote effect to modulate the neuronal activities of the brainstem and
forebrain [25–28], raising the possibility that burst SCS also exerts a therapeutic effect on the motor
symptoms of CD by normalizing the basal ganglia-thalamo-cortical circuit activity, the dysfunction of
which is tightly linked to the development of focal dystonia [29]. Future studies with large cohorts
should elucidate the mechanisms by which burst SCS alleviates dystonic motor symptoms.
5. Conclusions
Dystonic neck pain is a disabling condition that markedly impairs the quality of life in patients
with CD. However, optimal therapies for painful CD are currently lacking. Among the variety of
therapeutic interventions, intramuscular BTX injection is considered the first-line therapy for CD;
however, few reports have addressed its efficacy and safety in patients with CD. Indeed, BTX therapy
did not yield satisfactory results in any of the three patients who received the treatment in the present
study. In contrast, we showed that burst SCS could produce sustained and significant improvements
in dystonic pain as well as motor symptoms in patients with painful CD. Further studies are necessary
to investigate the clinical efficacy of burst SCS in patients with CD.
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